Exenatide (synthetic exendin-4) showed marked HbA1c decline over 5 months in patients with type 2 diabetes failing oral agents in an open-label study. - Baron,A.; Poon,T.; Taylor,K.; Nielsen,L.; Boies,S.; Zhou,J.; Zhuang,D.; Varns,A.; Kim,D.; Fineman,M.; Kolterman,O. (Diabetes, 2003)